AstraZeneca signed potential billion-dollar licensing deals with CSPC and Sino Biopharm, Hengrui's Kaleira-partnered oral GLP-1 candidate reported obesity and diabetes phase 3 data from China, and biotech insiders decried certain U.S. lawmakers' scrutiny over Chinese clinical trials as a distraction. And more.
Source: FiercePharma
